{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:13:06Z","timestamp":1787166786896,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lipoprotein(a) (Lp(a)) is an independent risk factor for myocardial infarction and aortic valve stenosis. European guidelines recommend assessing it at least once in a lifetime, particularly in premature atherosclerotic heart disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A non-interventional registry was conducted at MEDIAN rehabilitation facilities in Germany to assess the frequency of Lp(a) testing in referring acute care hospitals and the prevalence of elevated Lp(a) levels in aortic valve stenosis or premature myocardial infarction. All consecutive patients referred after coronary intervention or aortic valve surgery were included in four cohorts: aortic valve intervention (cohort 1), current\/previous myocardial infarction at\u2009&lt;\u200960 years of age (cohorts 2a\/2b), and myocardial infarction at\u2009\u2265\u200960 years of age (control).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The analysis included 3393 patient records (cohort 1,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091063; cohort 2a,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091351; cohort 2b,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009381; control,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009598). Lp(a) had been determined at the referring hospital in 0.19% (cohort 1), 4.96% (cohort 2a), 2.36% (cohort 2b), and 2.01% (control) of patients. Lp(a) levels were\u2009&gt;\u200950 mg\/dL or\u2009&gt;\u2009125 nmol\/L in 28.79% (cohort 1), 29.90% (cohort 2a), and 36.48% (cohort 2b;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) compared to 24.25% (control). Family history of premature cardiovascular disease was reported in 13.45% (cohort 1), 38.56% (cohort 2a), and 32.81% (cohort 2b) compared to 17.89% (control;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 for each comparison).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lp(a) had been rarely assessed in acute management of aortic valve stenosis or premature myocardial infarction despite expanding scientific evidence and guideline recommendation. Given the above-average incidence of elevated Lp(a) levels, awareness for Lp(a) has to increase substantially to better identify and manage high-risk patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-024-02427-0","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T04:01:56Z","timestamp":1713153716000},"page":"198-207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of elevated lipoprotein(a) in cardiac rehabilitation patients \u2014 results from a large-scale multicentre registry in Germany"],"prefix":"10.1007","volume":"115","author":[{"given":"Christoph","family":"Altmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelu-Adrian","family":"Burlacu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Preuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annett","family":"Hlousek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Eddicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the MEDIAN Medical Board Cardiology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Brezger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Eddicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erind","family":"Gjermeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Otto","family":"Schueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schueth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Slezakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Toepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Valenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Friederichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Ira","family":"Fru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Rahbarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raik","family":"Severin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Stancu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Turovets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Golenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"issue":"16","key":"2427_CR1","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1093\/eurjpc\/zwac132","volume":"29","author":"H Wienbergen","year":"2022","unstructured":"Wienbergen H, Boakye D, G\u00fcnther K, Schmucker J, Mata Mar\u00edn LA, Kerniss H et al (2022) Lifestyle and metabolic risk factors in patients with early-onset myocardial infarction: a case-control study. Eur J Prev Cardiol 29(16):2076\u20132087","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"2427_CR2","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.amjcard.2015.09.022","volume":"116","author":"A Fach","year":"2015","unstructured":"Fach A, B\u00fcnger S, Zabrocki R, Schmucker J, Conradi P, Garstka D et al (2015) Comparison of outcomes of patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention analyzed by age groups (<75, 75 to 85, and >85 Years); (Results from the Bremen STEMI Registry). Am J Cardiol 116(12):1802\u20131809","journal-title":"Am J Cardiol"},{"issue":"39","key":"2427_CR3","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 43(39):3925\u20133946","journal-title":"Eur Heart J"},{"issue":"2","key":"2427_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","volume":"117","author":"PR Kamstrup","year":"2008","unstructured":"Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG (2008) Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 117(2):176\u2013184","journal-title":"Circulation"},{"issue":"5","key":"2427_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","volume":"63","author":"PR Kamstrup","year":"2014","unstructured":"Kamstrup PR, Tybj\u00e6rg-Hansen A, Nordestgaard BG (2014) Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 63(5):470\u2013477","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2427_CR6","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","volume":"139","author":"G Par\u00e9","year":"2019","unstructured":"Par\u00e9 G, \u00c7aku A, McQueen M, Anand SS, Enas E, Clarke R et al (2019) Lipoprotein(a) Levels and the risk of myocardial infarction among 7 ethnic groups. Circulation 139(12):1472\u20131482","journal-title":"Circulation"},{"issue":"1","key":"2427_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"issue":"24","key":"2427_CR8","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"M Grundy Scott","year":"2019","unstructured":"Grundy Scott M, Stone Neil J, Bailey Alison L, Beam C, Birtcher Kim K, Blumenthal Roger S et al (2019) 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA GUIDELINE on the management of blood cholesterol: executive summary. J Am Coll Cardiol 73(24):3168\u20133209","journal-title":"J Am Coll Cardiol"},{"key":"2427_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2023.01.014","volume":"367","author":"PE St\u00fcrzebecher","year":"2023","unstructured":"St\u00fcrzebecher PE, Schorr JJ, Klebs SHG, Laufs U (2023) Trends and consequences of lipoprotein(a) testing: cross-sectional and longitudinal health insurance claims database analyses. Atherosclerosis 367:24\u201333","journal-title":"Atherosclerosis"},{"issue":"23","key":"2427_CR10","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF et al (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31(23):2844\u20132853","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"2427_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11789-017-0087-y","volume":"12","author":"F van Buuren","year":"2017","unstructured":"van Buuren F, Horstkotte D, Knabbe C, Hinse D, Mellwig KP (2017) Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease. Clin Res Cardiol Suppl 12(Suppl 1):55\u201359","journal-title":"Clin Res Cardiol Suppl"},{"issue":"40","key":"2427_CR12","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1093\/eurheartj\/ehaa034","volume":"41","author":"A Allahyari","year":"2020","unstructured":"Allahyari A, Jernberg T, Hagstrom E, Leosdottir M, Lundman P, Ueda P (2020) Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. Eur Heart J 41(40):3900\u20133909","journal-title":"Eur Heart J"},{"issue":"9","key":"2427_CR13","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1007\/s00392-022-02147-3","volume":"112","author":"U Makhmudova","year":"2023","unstructured":"Makhmudova U, Samadifar B, Maloku A, Haxhikadrija P, Geiling JA, Romer R et al (2023) Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (\u201cJena auf Ziel\u201d). Clin Res Cardiol 112(9):1212\u20131219","journal-title":"Clin Res Cardiol"},{"issue":"35\u201336","key":"2427_CR14","first-page":"582","volume":"120","author":"KG Parhofer","year":"2023","unstructured":"Parhofer KG, Laufs U (2023) Lipid profile and lipoprotein(a) testing. Dtsch Arztebl Int 120(35\u201336):582\u2013588","journal-title":"Dtsch Arztebl Int"},{"issue":"12","key":"2427_CR15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1001\/jamacardio.2023.3548","volume":"8","author":"LF Reeskamp","year":"2023","unstructured":"Reeskamp LF, Tromp TR, Patel AP, Ibrahim S, Trinder M, Haidermota S et al (2023) Concordance of a high lipoprotein(a) concentration among relatives. JAMA Cardiology 8(12):1111\u20131118","journal-title":"JAMA Cardiology"},{"key":"2427_CR16","unstructured":"Scheel P, Meyer J, Blumenthal RS, Martin SS (2019) Lipoprotein(a) in clinical practice. Available from https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2019\/07\/02\/08\/05\/lipoproteina-in-clinical-practice. Accessed 12 Oct 2023"},{"issue":"3","key":"2427_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1161\/CIRCULATIONAHA.123.066398","volume":"149","author":"M Szarek","year":"2024","unstructured":"Szarek M, Reijnders E, Jukema JW, Bhatt DL, Bittner VA, Diaz R et al (2024) Relating lipoprotein(a) concentrations to cardiovascular event risk after acute coronary syndrome: a comparison of three tests. Circulation 149(3):192\u2013203","journal-title":"Circulation"},{"issue":"3","key":"2427_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s00392-020-01788-6","volume":"110","author":"L Gaede","year":"2021","unstructured":"Gaede L, Blumenstein J, Husser O, Liebetrau C, D\u00f6rr O, Grothusen C et al (2021) Aortic valve replacement in Germany in 2019. Clin Res Cardiol 110(3):460\u2013465","journal-title":"Clin Res Cardiol"},{"issue":"15","key":"2427_CR19","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/eurheartj\/ehu043","volume":"35","author":"E Freisinger","year":"2014","unstructured":"Freisinger E, Fuerstenberg T, Malyar NM, Wellmann J, Keil U, Breithardt G et al (2014) German nationwide data on current trends and management of acute myocardial infarction: discrepancies between trials and real-life. Eur Heart J 35(15):979\u2013988","journal-title":"Eur Heart J"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02427-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-024-02427-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02427-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:37:11Z","timestamp":1768995431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-024-02427-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2427"],"URL":"https:\/\/doi.org\/10.1007\/s00392-024-02427-0","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"assertion":[{"value":"29 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The registry was in accordance with all relevant guidelines and regulations applicable in Germany. According to local regulations, neither ethics committee approval nor registration was required due to the non-interventional design and the absence of any drug effectiveness assessment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent to data collection, processing, and analysis was obtained from all patients prior to data collection. Patient data were anonymized and aggregated for analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Christoph Altmann has received speaker honoraria and compensation for serving on advisory boards, as well as project, research, and event funding, and served as clinical investigator in clinical studies sponsored by Pfizer, Amgen, Amarin, Novartis, Daiichi Sankyo, and Astra Zeneca. Nelu-Adrian Burlacu, Thomas Preuss, and Annett Hlousek declare no conflict of interests. Stephan Eddicks has received speaker honoraria and event funding by Pfizer, Amgen, Amarin, Novartis, Daiichi Sankyo, and Astra Zeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}